These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 4575333)
1. [Oral and nasal immunization with Poxvirus vacciniae. I. Criteria for smallpox immunity and immunology of the conventional cutaneous reaction to vaccination]. Hochstein-Mintzel V Zentralbl Bakteriol Orig B; 1972 Aug; 156(1):1-14. PubMed ID: 4575333 [No Abstract] [Full Text] [Related]
2. [Oral and nasal immunization with Poxvirus vacciniae. II. New methods of smallpox vaccination]. Hochstein-Mintzel V; Stickl H; Huber HC Zentralbl Bakteriol Orig B; 1972 Aug; 156(1):15-29. PubMed ID: 4575332 [No Abstract] [Full Text] [Related]
3. Oral immunization against smallpox. Hochstein-Mintzel V; Stickl H; Huber HC Dev Biol Stand; 1976; 33():260-6. PubMed ID: 182585 [TBL] [Abstract][Full Text] [Related]
4. [Oral and nasal immunization with poxvirus vacciniae. IV. Studies of oral immunization in monkeys]. Huber HC; Hochstein-Mintzel V; Rauchenberger P; Stickl H Zentralbl Bakteriol Orig B; 1973 May; 157(2):102-14. PubMed ID: 4200193 [No Abstract] [Full Text] [Related]
6. Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine: vaccinia Tiantan strain. Lu B; Yu W; Huang X; Wang H; Liu L; Chen Z J Biomed Biotechnol; 2011; 2011():970424. PubMed ID: 21765641 [TBL] [Abstract][Full Text] [Related]
7. [The comparative study of the safety of a vaccinal process in both oral and epicutaneous immunization against smallpox]. Bektimirov TA; Podkuĭko VN; Grigor'eva LV; Perekrest VV; Mikhaĭlov VV; Tereshkina NV; Dorokhina TV Vopr Virusol; 2002; 47(4):9-13. PubMed ID: 12271729 [TBL] [Abstract][Full Text] [Related]
8. Smallpox vaccination of eczema patients with attenuated live vaccinia virus. Kempe CH Yale J Biol Med; 1968 Aug; 41(1):1-12. PubMed ID: 5683825 [No Abstract] [Full Text] [Related]
9. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Stickl H; Hochstein-Mintzel V; Mayr A; Huber HC; Schäfer H; Holzner A Dtsch Med Wochenschr; 1974 Nov; 99(47):2386-92. PubMed ID: 4426258 [No Abstract] [Full Text] [Related]
10. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine. Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548 [TBL] [Abstract][Full Text] [Related]
11. Determination of immunity to vaccinia virus by using diluted inactivated vaccinia vaccine solution for skin testing. Somekh E; Smetana Z; Tanay A; Dalal I; Babai I; Mendelson E Vaccine; 2004 Dec; 23(3):321-4. PubMed ID: 15530675 [TBL] [Abstract][Full Text] [Related]
12. The persistence of humoral and cellular immunities more than three decades after smallpox vaccination. Kim SH; Yeo SG; Park KH; Bang JW; Kim HB; Kim NJ; Jee Y; Cho H; Oh MD; Choe KW Clin Microbiol Infect; 2007 Jan; 13(1):91-3. PubMed ID: 17184294 [TBL] [Abstract][Full Text] [Related]
13. Development of vaccination immunity in hospital personnel revaccinated at three-year intervals. Nyerges G; Hollós I; Losonczy G; Erdös L; Petrás G Acta Microbiol Acad Sci Hung; 1972; 19(1):63-8. PubMed ID: 4651044 [No Abstract] [Full Text] [Related]
14. Third-generation smallpox vaccines: challenges in the absence of clinical smallpox. Meseda CA; Weir JP Future Microbiol; 2010 Sep; 5(9):1367-82. PubMed ID: 20860482 [TBL] [Abstract][Full Text] [Related]
15. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. Edghill-Smith Y; Venzon D; Karpova T; McNally J; Nacsa J; Tsai WP; Tryniszewska E; Moniuszko M; Manischewitz J; King LR; Snodgrass SJ; Parrish J; Markham P; Sowers M; Martin D; Lewis MG; Berzofsky JA; Belyakov IM; Moss B; Tartaglia J; Bray M; Hirsch V; Golding H; Franchini G J Infect Dis; 2003 Oct; 188(8):1181-91. PubMed ID: 14551889 [TBL] [Abstract][Full Text] [Related]
16. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492 [TBL] [Abstract][Full Text] [Related]
17. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917 [TBL] [Abstract][Full Text] [Related]
19. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. McCurdy LH; Larkin BD; Martin JE; Graham BS Clin Infect Dis; 2004 Jun; 38(12):1749-53. PubMed ID: 15227622 [TBL] [Abstract][Full Text] [Related]
20. The effect of the number of incisions used in primary vaccination against smallpox on the intensity of antibody formation: a preliminary communication. Shneyderman AE; Petranovskaya MR; Marennikova SS J Hyg Epidemiol Microbiol Immunol; 1973 Mar; 17(3):257-60. PubMed ID: 4795563 [No Abstract] [Full Text] [Related] [Next] [New Search]